🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 5 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/06/2006 | 31,58 | 33,29 | 31,50 | 32,98 | +5,20% | 5,67% | 1.688.600 |
| 14/06/2006 | 29,69 | 31,48 | 29,68 | 31,35 | +5,27% | 6,06% | 1.460.100 |
| 13/06/2006 | 30,53 | 31,33 | 29,50 | 29,78 | -2,07% | 5,99% | 1.239.800 |
| 12/06/2006 | 31,88 | 32,36 | 30,20 | 30,41 | -4,97% | 6,78% | 1.343.600 |
| 09/06/2006 | 32,21 | 33,19 | 31,42 | 32,00 | +0,28% | 5,50% | 1.329.300 |
| 08/06/2006 | 31,51 | 32,21 | 30,47 | 31,91 | +0,50% | 5,52% | 1.535.700 |
| 07/06/2006 | 31,76 | 33,03 | 31,41 | 31,75 | -0,44% | 5,10% | 999.900 |
| 06/06/2006 | 31,44 | 32,90 | 30,70 | 31,89 | +1,43% | 7,00% | 1.573.000 |
| 05/06/2006 | 34,50 | 34,72 | 31,38 | 31,44 | -9,32% | 9,68% | 2.146.300 |
| 02/06/2006 | 34,60 | 34,97 | 34,07 | 34,67 | +0,93% | 2,60% | 1.116.400 |
| 01/06/2006 | 34,50 | 34,91 | 33,74 | 34,35 | -0,43% | 3,39% | 1.664.600 |
| 31/05/2006 | 32,87 | 35,00 | 32,85 | 34,50 | +5,76% | 6,54% | 4.798.800 |
| 30/05/2006 | 33,58 | 33,90 | 32,50 | 32,62 | -3,35% | 4,17% | 1.082.000 |
| 26/05/2006 | 33,10 | 33,84 | 32,72 | 33,75 | +1,56% | 3,38% | 994.900 |
| 25/05/2006 | 32,19 | 33,79 | 32,10 | 33,23 | +4,17% | 5,25% | 1.590.900 |
| 24/05/2006 | 31,45 | 32,28 | 30,33 | 31,90 | +3,74% | 6,20% | 2.625.400 |
| 23/05/2006 | 29,91 | 31,65 | 29,91 | 30,75 | +4,41% | 5,82% | 2.419.100 |
| 22/05/2006 | 30,05 | 30,47 | 29,10 | 29,45 | -2,64% | 4,56% | 2.036.900 |
| 19/05/2006 | 29,49 | 30,80 | 29,13 | 30,25 | +3,38% | 5,66% | 2.048.000 |
| 18/05/2006 | 31,10 | 31,93 | 29,00 | 29,26 | -5,70% | 9,42% | 2.479.700 |
| 17/05/2006 | 31,98 | 32,67 | 30,56 | 31,03 | -3,99% | 6,60% | 1.789.100 |
| 16/05/2006 | 33,20 | 33,37 | 32,05 | 32,32 | -2,68% | 3,98% | 1.451.300 |
| 15/05/2006 | 33,73 | 34,07 | 32,52 | 33,21 | -3,01% | 4,60% | 1.504.700 |
| 12/05/2006 | 35,01 | 35,24 | 33,39 | 34,24 | -3,00% | 5,28% | 1.587.900 |
| 11/05/2006 | 35,50 | 36,13 | 34,85 | 35,30 | +0,06% | 3,61% | 1.374.300 |
| 10/05/2006 | 35,45 | 36,14 | 34,92 | 35,28 | -1,04% | 3,44% | 828.300 |
| 09/05/2006 | 36,15 | 36,33 | 35,46 | 35,65 | -1,82% | 2,41% | 681.700 |
| 08/05/2006 | 37,00 | 37,15 | 36,07 | 36,31 | -1,73% | 2,92% | 545.700 |
| 05/05/2006 | 35,88 | 37,19 | 35,75 | 36,95 | +3,82% | 4,01% | 1.072.400 |
| 04/05/2006 | 34,94 | 35,73 | 34,63 | 35,59 | +1,63% | 3,15% | 817.800 |